Harrison, S., Ho, P. J., Lim, S., Talam, S., Pahl, H., Dingar, D., Currence, S., Quigley, T., Spencer, A. (2025). Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. https://doi.org/10.1182/blood-2025-lba-1